Evaluation of S100A12 and Apo-A1 plasma level potency in untreated new relapsing–remitting multiple sclerosis patients and their family members

[1]  M. Shohani,et al.  Epidemiology of multiple sclerosis in Iran: A systematic review and meta-analysis , 2019, PloS one.

[2]  M. Taheri,et al.  Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in Multiple Sclerosis Patients Treated with Interferon β-1a , 2018, Cellular Physiology and Biochemistry.

[3]  S. Eskandarieh,et al.  Increasing prevalence of familial recurrence of multiple sclerosis in Iran: a population based study of Tehran registry 1999–2015 , 2018, BMC Neurology.

[4]  J. Oksenberg,et al.  Multiple sclerosis genetics. , 2018, Current topics in microbiology and immunology.

[5]  Jixin Zhong,et al.  S100 Proteins As an Important Regulator of Macrophage Inflammation , 2018, Front. Immunol..

[6]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[7]  N. Shahrokhi,et al.  Interferon-β 1a Modulates Expression of RAGE but Not S100A12 and Nuclear Factor-κB in Multiple Sclerosis Patients , 2017, Neuroimmunomodulation.

[8]  S. Razavi,et al.  Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy , 2016, Cell journal.

[9]  Jinxiang Han,et al.  Estimating epidemiological data of Multiple sclerosis using hospitalized data in Shandong Province, China , 2016, Orphanet Journal of Rare Diseases.

[10]  J. Meephansan,et al.  Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis , 2016, International journal of molecular sciences.

[11]  M. Buhse.  The Elderly Person With Multiple Sclerosis: Clinical Implications for the Increasing Life-Span , 2015, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[12]  M. Levin,et al.  A role for Apolipoprotein A-I in the pathogenesis of multiple sclerosis , 2014, Journal of Neuroimmunology.

[13]  P. Ueda,et al.  Neonatal vitamin D status and risk of multiple sclerosis , 2014, Annals of neurology.

[14]  B. Cheraghian,et al.  Comparison of Antioxidant Status and Vitamin D Levels between Multiple Sclerosis Patients and Healthy Matched Subjects , 2014, Multiple sclerosis international.

[15]  D. Romić,et al.  Decreased Level of sRAGE in the Cerebrospinal Fluid of Multiple Sclerosis Patients at Clinical Onset , 2014, Neuroimmunomodulation.

[16]  Helena Brisby,et al.  Increased CSF Levels of Phosphorylated Neurofilament Heavy Protein following Bout in Amateur Boxers , 2013, PloS one.

[17]  M. Etemadifar,et al.  Epidemiology of Multiple Sclerosis in Iran: A Systematic Review , 2013, European Neurology.

[18]  A. Palmer.  Multiple Sclerosis and the Blood-Central Nervous System Barrier , 2013, Cardiovascular psychiatry and neurology.

[19]  N. Bizzaro,et al.  Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. , 2012, Autoimmunity reviews.

[20]  S. Broadley,et al.  Modelling Genetic Susceptibility to Multiple Sclerosis with Family Data , 2012, Neuroepidemiology.

[21]  J. Parks,et al.  Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers[S] , 2012, Journal of Lipid Research.

[22]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[23]  M. Ramanathan,et al.  Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis , 2011, Journal of Neuroinflammation.

[24]  H. Lassmann.  Pathophysiology of inflammation and tissue injury in multiple sclerosis: What are the targets for therapy , 2011, Journal of the Neurological Sciences.

[25]  H. Hanwell,et al.  Assessment of evidence for a protective role of vitamin D in multiple sclerosis. , 2011, Biochimica et biophysica acta.

[26]  M. Sahraian,et al.  Multiple Sclerosis in Iran: A Demographic Study of 8,000 Patients and Changes over Time , 2010, European Neurology.

[27]  J. Arthur,et al.  Novel Approaches to Detect Serum Biomarkers for Clinical Response to Interferon-β Treatment in Multiple Sclerosis , 2010, PloS one.

[28]  E. Kahana,et al.  Multiple sclerosis: geoepidemiology, genetics and the environment. , 2010, Autoimmunity reviews.

[29]  M. Brown,et al.  Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis , 2009, Arthritis research & therapy.

[30]  G. Koutsis,et al.  An APOA1 promoter polymorphism is associated with cognitive performance in patients with multiple sclerosis , 2009, Multiple sclerosis.

[31]  R. D'Hooge,et al.  Absence of Functional Peroxisomes from Mouse CNS Causes Dysmyelination and Axon Degeneration , 2008, The Journal of Neuroscience.

[32]  D. Foell,et al.  S100 proteins expressed in phagocytes: a novel group of damage‐associated molecular pattern molecules , 2007, Journal of leukocyte biology.

[33]  A. Ascherio,et al.  Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.

[34]  S. Pozzi,et al.  Estrogen Action in Neuroprotection and Brain Inflammation , 2006, Annals of the New York Academy of Sciences.

[35]  Jan-Gowth Chang,et al.  Proteomic Identification of Lower Apolipoprotein A-I in Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.

[36]  M. Melbye,et al.  Familial risk of multiple sclerosis: a nationwide cohort study. , 2005, American journal of epidemiology.

[37]  L. Panin,et al.  Apolipoprotein A-I Possessing Activity of Defensin Proteins Modifies Structure of Plasma Membranes , 2005, Bulletin of Experimental Biology and Medicine.

[38]  F. Jessen,et al.  APOA1 polymorphism influences risk for early‐onset nonfamiliar AD , 2005, Annals of neurology.

[39]  J. Dayer,et al.  High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? , 2002, Autoimmunity reviews.

[40]  Terence Dwyer,et al.  Regional Variation in Multiple Sclerosis Prevalence in Australia and Its Association with Ambient Ultraviolet Radiation , 2001, Neuroepidemiology.

[41]  R. Donato,et al.  Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. , 1999, Biochimica et biophysica acta.

[42]  A. Sadovnick,et al.  Risks of multiple sclerosis in relatives of patients in Flanders, Belgium. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[43]  T. Yaginuma,et al.  Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease. , 1995, Clinica chimica acta; international journal of clinical chemistry.

[44]  Roland Martin,et al.  The good and the bad of neuroinflammation in multiple sclerosis. , 2014, Handbook of clinical neurology.